Results 171 to 180 of about 109,906 (243)

Preoperative continuation vs. discontinuation of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on early cognitive function in elderly patients undergoing noncardiac surgery: a randomized controlled trial. [PDF]

Front Aging Neurosci
Wang X, Yan Y, Liu Y, Xu C, Zhuang J, Wang Z.   +5 more
europepmc   +1 more source

Maternal exercise improves vascular function in hypertensive offspring via A‐kinase anchoring protein 150 gene (Akap5) epigenetic modifications

British Journal of Pharmacology, EarlyView.
Background and Purpose Regular physical activity is an effective non‐pharmacological approach to hypertension management and maternal exercise improves offspring cardiovascular health, although mechanisms remain unclear. A‐kinase anchoring protein 150 (AKAP150) targets protein kinase Cα to L‐type Ca2+ channels (CaV1.2), enhancing vascular tone in ...
Fang Qiu, Yanyan Zhang, Meiling Shan, Jiaqi Cao, Zihan Fan, Zhaoxia Xu, Xiaozhen Ding, Xiaodong Liu, Lijun Shi   +8 more
wiley   +1 more source

A Meta-Analysis of the Impact of Using Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) on Mortality, Severity, and Healthcare Resource Utilization in Patients with COVID-19. [PDF]

Adv Respir Med
Li R, Zhang J, Ren L.
europepmc   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source

Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. [PDF]

Cochrane Database Syst Rev
Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF.   +4 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. [PDF]

Clin Genitourin Cancer
Skelton WP, Masur J, Thomas J, Fallah P, Jain RK, Ravi P, Mantia C, McGregor BA, Nuzzo PV, Adib E, Zarif TE, Preston MA, Clinton TN, Li R, Steele GS, Kassouf W, Freeman D, Pond GR, Jain RK, Sonpavde GP.   +19 more
europepmc   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

A network meta-analysis comparative the efficacy of angiotensin-converting enzyme inhibitors and calcium channel blockers in hypertension. [PDF]

Medicine (Baltimore)
Yao YJ, Gui M, Cai SK.
europepmc   +1 more source

Algorithms in Allergy: Hereditary Angioedema

Allergy, EarlyView.
Konrad Bork, Markus Magerl, Emel Aygören‐Pürsün, Henriette Farkas   +3 more
wiley   +1 more source